Keywords: wyeth-ayerst, effexor, xr, gains, label, long-term, gad
Wyeth-Ayerst's Effexor XR gains label for long-term GAD
Article | 20 July 2000
The US Food and Drug Administration has granted Wyeth-Ayerst clearanceto promote its antidepressant Effexor XR (venlafaxine extended-release) for use as ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
